Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    Kisspeptin-10

    Hormones & Endocrine (Non-GH)

    Status
    Phase 2, , not approved for human use
    Evidence

    Not graded on a research bench yet

    Kisspeptin-10 (KP-10, metastin 45-54) is the C-terminal decapeptide fragment of kisspeptin, a neuropeptide product of the KISS1 gene that has emerged over the past two decades as the master regulator of reproductive endocrinology in humans and all other vertebrates studied to date.

    Reviewed

    01Overview

    What Kisspeptin-10 is

    The KISS1 gene was originally cloned in 1996 in Hershey, Pennsylvania (and named after the town's iconic Hershey Kiss), initially as a metastasis-suppressor gene in melanoma cell lines. Its true reproductive function wasn't understood until 2003, when two independent research groups — one led by Nicolas de Roux in Paris and another by Stephanie Seminara at Massachusetts General Hospital — discovered that loss-of-function mutations in the G-protein-coupled receptor GPR54 (now named KISS1R) caused hypogonadotropic hypogonadism with failure of puberty. This finding transformed kisspeptin from an obscure tumor-biology gene into the gatekeeper of the entire hypothalamic-pituitary-gonadal (HPG) axis (de Roux et al., 2003, Seminara et al., 2003).

    Read the full overviewShow less

    Kisspeptin is synthesized as a 145-amino-acid precursor prohormone that is processed into several bioactive peptides: kisspeptin-54 (KP-54, the longest form), kisspeptin-14, kisspeptin-13, and kisspeptin-10. KP-10 retains essentially all of the biological potency of the parent molecule at the KISS1R receptor, making it the most practical form for research and therapeutic exploration — it is smaller, more stable, easier to synthesize, and equally efficacious. Kisspeptin neurons in the hypothalamus (located in the arcuate nucleus and the preoptic area / AVPV) project to GnRH neurons and release kisspeptin as the essential upstream stimulus that drives GnRH release. Without kisspeptin signaling, GnRH neurons fire infrequently or not at all, and the entire reproductive axis — LH, FSH, testosterone, estrogen, ovulation, spermatogenesis — shuts down. This is why congenital KISS1R mutations cause such a dramatic reproductive phenotype despite the rest of the HPG axis being intact ([Messager et al., 2005]).

    In current clinical and research practice, kisspeptin (usually as KP-10 or KP-54) is being investigated for a range of reproductive applications: as a diagnostic probe for the integrity of the HPG axis (an alternative to or supplement to GnRH stimulation testing), as an ovulation trigger in in-vitro fertilization cycles (where it may reduce ovarian hyperstimulation syndrome risk compared to hCG), as a therapy for hypothalamic amenorrhea and functional hypothalamic hypogonadism, and as an investigational treatment for hypoactive sexual desire disorder (HSDD), with emerging work on mood and anxiety effects as well. Kisspeptin is not currently approved for any indication in the United States, but Phase II data from Imperial College London and other centers have been promising enough that pharmaceutical development is underway ([Dhillo et al., 2005], [Abbara et al., 2015]).

    Off-label and peptide-community interest in KP-10 centers on two use cases. First, men using suppressive regimens — testosterone replacement therapy, anabolic steroid cycles, or GnRH-axis-affecting drugs — sometimes use KP-10 during "post-cycle" recovery phases on the theory that stimulating endogenous GnRH release may accelerate HPG axis recovery faster than the conventional Gonadorelin (GnRH) or HCG (Human Chorionic Gonadotropin) approaches. The evidence base for this use is thin — kisspeptin's efficacy in restoring suppressed axes after exogenous androgens has not been formally studied — but mechanistically plausible. Second, some researchers and a small community of users are interested in kisspeptin's effects on sexual desire and mood, which appear to be separable from its reproductive effects and mediated by kisspeptin receptor expression in limbic structures like the amygdala ([Comninos et al., 2017]).

    KP-10 is a legitimate research tool with meaningful clinical promise and an unusually well-characterized physiological mechanism. Unlike many grey-market peptides, the clinical evidence base is growing and the safety profile in short-term human trials at reproductive-axis doses has been clean. This entry covers KP-10's known biology, its current and investigational uses, and the considerable uncertainties that remain — particularly around long-term dosing, optimal regimens for axis recovery, and whether peripheral KP-10 administration reproduces the physiological effects of endogenous kisspeptin neuron firing.

    How it works

    Kisspeptin-10 signals through a single G-protein-coupled receptor, KISS1R (formerly GPR54), expressed prominently on GnRH neurons in the hypothalamus and at lower levels in multiple peripheral tissues including placenta, gonads, and the central nervous system reward circuitry. The pharmacology is elegant and relatively simple in mechanism but drives a complex downstream physiology:

    Primary Hypothalamic Effect — GnRH Release: KISS1R activation is coupled predominantly to Gαq/11, which activates phospholipase C, generates inositol trisphosphate (IP3) and diacylglycerol (DAG), raises intracellular calcium, and triggers GnRH release from GnRH neuron terminals in the median eminence. Kisspeptin is currently understood to be the obligate upstream driver of pulsatile GnRH release — the GnRH neurons themselves generate the pulse timing, but kisspeptin input controls whether and how strongly they fire. Under physiological conditions, kisspeptin neurons in the arcuate nucleus (the "KNDy" neurons, which also express neurokinin B and dynorphin) fire synchronously to generate GnRH pulses, while kisspeptin neurons in the preoptic area (AVPV) drive the GnRH surge responsible for the mid-cycle LH surge in females.

    Read the full mechanismShow less

    Downstream HPG Axis Activation: GnRH released from the median eminence travels through the hypophyseal portal circulation to the anterior pituitary, where it stimulates gonadotroph cells to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates gonadal testosterone or estrogen production and triggers ovulation in females; FSH drives spermatogenesis in males and follicular development in females. The entire cascade — KP-10 → GnRH → LH/FSH → gonadal steroids → gametogenesis — takes roughly 20-60 minutes from IV or SC kisspeptin administration to measurable LH/FSH rise in plasma.

    Selectivity and Signaling Bias: KP-10 is a high-affinity full agonist at KISS1R with IC50 in the low-nanomolar range. There is no significant cross-reactivity with other GPCRs. Signaling bias studies suggest that kisspeptin preferentially engages Gαq pathways over β-arrestin recruitment, which may contribute to its relatively favorable desensitization profile compared to GnRH analogs. Continuous high-dose kisspeptin exposure does eventually produce GnRH-axis downregulation, but pulsatile or intermittent dosing appears to maintain responsiveness.

    Extrapituitary Effects:

    • Limbic system (amygdala, hippocampus, cingulate cortex): KISS1R expression in limbic structures mediates kisspeptin's effects on sexual desire, emotional processing, and mood. Comninos and colleagues at Imperial College have shown using fMRI that kisspeptin administration in men enhances brain activity in reward/arousal circuits in response to sexual and romantic cues, and attenuates activity in regions associated with negative mood and anxiety ([Comninos et al., 2017]).
    • Gonads (direct): KISS1R is expressed on theca and granulosa cells of the ovary and on Leydig cells of the testis; direct local kisspeptin signaling may modulate steroidogenesis and gamete maturation, though the physiological significance of these peripheral actions in kisspeptin-treated subjects is uncertain.
    • Placenta: Kisspeptin is produced in large amounts by trophoblasts and is thought to regulate trophoblast invasion and placental development. This is why plasma kisspeptin concentrations rise dramatically in pregnancy.

    Pharmacokinetics: KP-10 administered subcutaneously or intravenously has a plasma half-life of approximately 4 minutes — extremely short, reflecting rapid peptidase degradation. Despite this short half-life, the downstream LH/FSH response lasts 1-2 hours because the pituitary gonadotrophs require time to transcribe and secrete the hormones triggered by the initial GnRH pulse. Continuous infusion or repeated boluses produce sustained axis activation; single doses produce a single pulse-like LH/FSH rise. This short half-life is why kisspeptin preparations are usually administered either as continuous subcutaneous infusions (for ovulation induction or sustained axis stimulation) or as frequent bolus doses (for pulsatile stimulation mimicking endogenous physiology).

    Longer-Acting Forms: Researchers have developed both KP-54 (which has slightly longer half-life but still on the order of 30 minutes) and engineered kisspeptin analogs with PEGylation or other half-life-extending modifications. MVT-602 (from Myovant Sciences) is a kisspeptin analog with an approximate 60-90 minute half-life being investigated for clinical use. For most peptide-community use, plain KP-10 remains the most accessible form.

    Studied for

    • Hypogonadotropic hypogonadism
    • Fertility
    • Sexual dysfunction
    • Puberty disorders

    Benefits listed

    • LH/FSH stimulation
    • Testosterone support
    • Fertility enhancement
    • Sexual arousal
    Show 1 moreShow less
    • HPG axis activation

    02Research

    Free with email

    What the research shows

    No research bench grades Kisspeptin-10 yet. Benches compare compounds people pair, with the evidence for each.

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    03Safety

    Kisspeptin-10 side effects and interactions

    Side effects

    Low risk

    Stop use if

    • Hormone-sensitive cancers
    • Pregnancy (outside clinical protocol)

    Common

    • Mild flushing
    • Nausea
    • Headache
    • LH/testosterone surge (expected)

    Less common

    • Ovarian hyperstimulation (women)
    • Mood changes

    Who should not use it

    Contraindications

    Absolute contraindications:

    • Hormone-sensitive cancers — prostate cancer, hormone-receptor-positive breast cancer, endometrial cancer. Kisspeptin drives endogenous sex steroid production, which can accelerate these malignancies.
    • Active pregnancy (outside of specifically supervised ovulation-induction protocols)
    • Known hypersensitivity to kisspeptin preparations
    • Age < 18 without pediatric endocrinology involvement
    • Untreated or poorly controlled pituitary adenomas (particularly gonadotropin-secreting adenomas)
    Read all the contraindications and cautionsShow less

    Strong relative contraindications:

    • Severe uncontrolled hypertension
    • Recent cardiovascular event (MI, stroke within 6 months)
    • Moderate-to-severe liver or kidney dysfunction (peptide clearance uncertain)
    • Active attempt at conception when timing is not desired (kisspeptin substantially raises fertility potential)
    • Personal history of estrogen-driven conditions (severe endometriosis, estrogen-responsive fibroids) where rising estrogen from re-activated axis may worsen symptoms
    • Individuals on hormonal therapies for gender transition (feminizing or masculinizing) who are not attempting to activate their endogenous axis — kisspeptin will counteract the hormonal regimen goals

    Drug interactions:

    • Opioids (chronic high-dose): Opioids suppress GnRH release downstream of kisspeptin signaling. Kisspeptin effect may be blunted in chronic opioid users.
    • GnRH antagonists (cetrorelix, degarelix) or GnRH agonists at suppressive doses (leuprolide): Pharmacological antagonism; do not combine.
    • Androgen deprivation therapy for prostate cancer: Absolute contraindication to kisspeptin.
    • Aromatase inhibitors (anastrozole, letrozole): Not a direct interaction but will alter the estrogen component of the axis response.
    • Dopamine agonists (bromocriptine, cabergoline): Dopamine suppresses kisspeptin neuron activity; chronic high-dose dopaminergics may reduce kisspeptin effect.
    • Exogenous androgens (testosterone, SARMs, anabolic steroids) during active dosing: Strong negative feedback will overwhelm upstream stimulation. Kisspeptin makes sense during recovery phases, not during active androgen suppression.

    Stop using if:

    • Any new breast lump, unusual bleeding, or prostate concerns
    • New or worsening mood symptoms
    • Severe headache, visual changes, or symptoms suggestive of pituitary pathology
    • Pregnancy (confirmed or suspected, outside of specific supervised protocols)
    • Unexplained sudden blood pressure rise

    Monitoring:

    • Baseline labs before starting: LH, FSH, total and free testosterone, estradiol, prolactin, SHBG, TSH, CBC, metabolic panel
    • Mid-cycle labs at 4-6 weeks: LH, FSH, total and free testosterone, estradiol
    • End-cycle labs at 8-12 weeks: full panel repeat
    • For women: menstrual cycle tracking; early pregnancy test if any cycle irregularity
    • For men in recovery phases: semen analysis at 3-6 months if fertility is a concern

    Medical Supervision: Kisspeptin is a legitimate research and emerging clinical tool. Users with access to endocrinology-literate physicians should strongly prefer supervised rather than independent use — axis recovery, desire effects, and any adverse events are far better managed with lab monitoring and clinical oversight.

    Interactions

    2 pairings in our record: 2 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.

    • Gonadorelin

      Synergistic

      Kisspeptin stimulates GnRH — natural HPG axis support

    • Enclomiphene

      Compatible

      Complementary hormonal axis support mechanisms

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    Order Bloodwork

    04Dosing

    Free with email

    Kisspeptin-10 dosage and protocols

    Unlock the dosing protocols

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • Dose, route, how often and how long
    • A titration schedule
    • Beginner, intermediate and advanced protocols
    • Reconstitution and handling notes

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    05Prices

    Kisspeptin-10 prices

    3 listings from 3 vendors, opening in the Featured order.

    Pack prices
    $39.99 to $54.99
    Lowest per mg
    $4.00/mg
    Vendors
    3
    Listings
    3 (vial)

    Prices as the vendors list them, last recorded 8 October 2026.

    Size
    Form
    Sort
    Kisspeptin-10 listings, in Featured order
    VendorProductPriceBuy

    Kisspeptin-10 10mg

    vial, 1 vial

    In stock

    $4.00/mg

    $39.99

    Lowest per mg
    Buy Kisspeptin-10 10mg at Optimum Formula

    Kisspeptin

    vial, 1 vial

    In stock

    $54.99

    No mg count

    Buy Kisspeptin at Disguised Alpha

    Kisspeptin-10 5mg

    vial, 5mg vial

    In stock

    $8.00/mg

    $39.99

    Buy Kisspeptin-10 5mg at Half Nattys
    Vendors selling Kisspeptin-10(3: trust score, certificates, payment, shipping)

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors

    Price history(3 days with a recorded price)
    Review Kisspeptin-10

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Kisspeptin-10.

    06Chemistry

    Chemistry and structure

    Molecular formula
    C63H83N17O14
    Molecular mass
    1302.46 g/mol
    CAS number
    374675-21-5
    IUPAC name
    Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
    Amino acid sequence
    Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (single-letter: YNWNSFGLRF-NH2). Human kisspeptin-10 is the C-terminally amidated decapeptide corresponding to metastin/KISS1 residues 45-54 (KISS1 112-121); the C-terminal Arg-Phe-NH2 is the RFamide motif required for KISS1R (GPR54) activation. Formula C63H83N17O14; CAS 374675-21-5.
    Half-life
    ~4 minutes (KP-10, plasma) - reflecting rapid peptidase degradation. The downstream LH/FSH response nonetheless persists ~1-2 hours after a dose. For comparison, kisspeptin-54 has a measured plasma half-life of ~27 minutes.
    View on PubChem

    08Questions

    Frequently asked questions

    What exactly does kisspeptin do that makes it so important?

    Kisspeptin is the master upstream regulator of the entire reproductive axis. It stimulates GnRH neurons in the hypothalamus to release GnRH, which then drives LH and FSH release from the pituitary, which then drives testosterone, estrogen, spermatogenesis, and ovulation from the gonads. Without kisspeptin signaling, the whole axis goes silent - people born with inactivating mutations in the kisspeptin receptor (KISS1R) fail to enter puberty. Because kisspeptin sits at the top of this cascade, exogenous kisspeptin can drive the entire axis downstream when administered, making it uniquely powerful among reproductive peptides.

    How is KP-10 different from KP-54?

    Both are endogenously produced kisspeptin peptides - KP-54 is the longer precursor cleavage product (54 amino acids), and KP-10 is the C-terminal decapeptide that retains essentially all the biological activity. KP-10 has a shorter plasma half-life (~4 minutes vs ~30 minutes for KP-54) but is functionally equivalent at the receptor. For most peptide-community use, KP-10 is more commonly available and equally effective for axis stimulation. Clinical research often uses KP-54 for applications like ovulation induction where the slightly longer half-life simplifies dosing.

    Can I use KP-10 during an active anabolic cycle?

    It will not work during active high-dose androgen administration. Exogenous androgens produce powerful negative feedback at both hypothalamus and pituitary, and this suppression overwhelms any upstream kisspeptin stimulation. KP-10 is useful during recovery phases (after exogenous androgens are cleared, typically 2-4 weeks post-cycle depending on ester) but not during active suppression. HCG, which acts directly at Leydig cell LH receptors in the testis and bypasses central suppression, is the appropriate on-cycle support for testicular function - kisspeptin becomes relevant afterward.

    How quickly will I feel KP-10 working?

    This depends on indication. For axis recovery after exogenous androgen suppression, effects are measured in lab trends over weeks - LH and FSH rises can be seen within days of starting, testosterone follows over 2-4 weeks, and full axis normalization often takes 6-12 weeks. Subjectively, most users notice returning morning erections, libido, and energy gradually over the first month rather than any dramatic acute change. For the central desire/HSDD effects, acute subjective changes (libido, emotional engagement) often occur within 1-2 hours of dosing. The axis and the limbic effects operate on different timescales.

    Is KP-10 safer than HCG or clomiphene for axis recovery?

    Short answer: side-effect profiles differ, and KP-10 looks cleanest in published trials, but no head-to-head long-term comparison study has been done. HCG maintains Leydig cell function during cycle but can desensitize LH receptors with prolonged use and does not address hypothalamic suppression. Clomiphene/enclomiphene act at the estrogen receptor and have well-documented vision and mood side effects in some users. KP-10 acts at the hypothalamus through a different mechanism without the desensitization or SERM side-effect concerns, but the long-term safety of repeated kisspeptin dosing has not been established. Most users of rigorous recovery protocols combine modalities rather than relying on any single agent.

    Will KP-10 make me fertile if I've been trying to conceive?

    Possibly yes, for both men and women. In men with suppressed axes from exogenous androgens or functional causes, kisspeptin-driven LH/FSH restoration can rebuild spermatogenesis over 3-6 months (one full spermatogenesis cycle). In women with functional hypothalamic amenorrhea, kisspeptin can restore ovulation; published trials have demonstrated live births following kisspeptin-triggered ovulation in IVF cycles. However, fertility is complicated and requires the entire reproductive system to be intact. Kisspeptin fixes upstream signaling but cannot compensate for primary gonadal failure, severe oligospermia from structural causes, or uterine/tubal factors. Fertility work should be medically supervised.

    Does KP-10 help with libido even if my testosterone is normal?

    Research suggests yes. Kisspeptin's effects on sexual desire and romantic processing operate through limbic brain regions (amygdala, hippocampus) that are pharmacologically separate from the HPG axis. Imperial College studies have shown fMRI evidence of enhanced sexual arousal circuit activation from kisspeptin even in eugonadal men, and clinical trials in women with HSDD have shown improvements in subjective desire that are not driven by testosterone or estrogen changes. This central mechanism appears to be distinct from the HPG-axis mechanism and is why kisspeptin is being pursued as a potential HSDD treatment. In practical use, some people with normal hormones experience meaningful subjective libido response to kisspeptin; others do not - individual response varies.

    What about kisspeptin and mood or anxiety?

    Preliminary research suggests kisspeptin may have anxiolytic effects and improve mood regulation in some populations, mediated through limbic kisspeptin receptors. Small trials and case studies have reported improvements in self-reported anxiety and mood during kisspeptin administration. However, this is not a clinical indication and the evidence base is much smaller than for reproductive effects. No one should substitute kisspeptin for evidence-based mental health treatment. If users notice mood benefits alongside reproductive effects, this is consistent with the emerging science but should not be the primary reason for use.

    Do I need to cycle KP-10?

    It depends on how you dose. This matters because human trials have actually shown clear tachyphylaxis under some schedules: twice-daily subcutaneous kisspeptin-54 injections in women with hypothalamic amenorrhea largely abolished the LH and FSH response within about two weeks of high-frequency bolus dosing. Spacing the same peptide out to twice-weekly avoided most of that desensitization while still raising reproductive hormones over eight weeks, and short studies of continuous KP-10 infusion have maintained responses - so the receptor does not inevitably desensitize, but frequent, sustained, high-dose bolus exposure clearly can blunt it. Because long-term data are absent, spacing doses and using defined cycles (for example, running an 8-12 week axis-recovery block around a specific goal and then discontinuing, rather than dosing indefinitely) is the prudent, conservative approach.

    Can women use KP-10 for axis recovery after hormonal contraceptive suppression?

    Possibly. Some women experience prolonged menstrual cycle irregularity after stopping long-term hormonal contraception, often reflecting functional hypothalamic suppression. Kisspeptin has shown efficacy in restoring cycles in hypothalamic amenorrhea trials and may theoretically help in post-contraceptive axis recovery. However, the evidence base for this specific application is thinner than for men's post-cycle recovery. Women considering kisspeptin for cycle restoration should ideally work with a reproductive endocrinologist and ensure that other causes of irregular cycles (thyroid, prolactinoma, PCOS) have been excluded. Pregnancy possibility during kisspeptin use in cycling women must be considered.

    How many vendors sell Kisspeptin-10, and what does it cost per mg?

    3 of the vendors BodyHackGuide tracks list Kisspeptin-10 (3 listings). Among BodyHackGuide's Kisspeptin-10 listings recorded as in stock with a milligram count, the lowest price per milligram is $4.00/mg at Optimum Formula and the median is $6.00/mg. The Kisspeptin-10 prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Kisspeptin-10 listing is dated 8 October 2026.

    Which vendors have third-party COAs for Kisspeptin-10 on file at BodyHackGuide?

    BodyHackGuide holds 67 third-party certificate records for Kisspeptin-10, from . No editor has read any of BodyHackGuide's 67 certificate records for Kisspeptin-10. The laboratory named on BodyHackGuide's Kisspeptin-10 certificate records is Freedom Diagnostics Testing, and the newest test date on them is 2 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

    Related

    Articles on Kisspeptin-10

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free